Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryHighmark Blueshield NENY Aimovig Prior Auth | Open…
    Ask Trek AI about this page
    CurrentHighmark Blueshield NenyPolicy N/A

    Medication Prior Authorization Form — Migraine Prophylaxis (Aimovig)

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This form governs prior authorization requests for migraine prevention medications (specifically Aimovig is referenced) for Highmark Blue Shield members in North Carolina and collects member, provider, medication, and clinical information to determine coverage.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyMedication prior authorization form for Aimovig (migraine prophylaxis)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a separate completed prior authorization form and all clinical documentation by fax to 1-866-240-8123 for each medication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1-866-240-8123fax number for submission
    50%reauthorization response threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4episodic migraine reduction
    1medication per form

    Coverage and Medical Necessity Criteria

    Initial Authorization Criteria

    Coverage considered when ALL of the following are documented:

    Baseline diagnosis: Provider documents member diagnosis as Episodic Migraine (4-14 headache days/month) or Chronic Migraine (15+ headache days/month)

    See form selection

    Baseline frequency: Provider documents average number of migraine days per month prior to therapy

    Used to assess initial eligibility and reauthorization

    Medication overuse/rebound: Provider confirms headaches are not primarily due to medication rebound/overutilization or lifestyle factors (e.g., >18 doses/month of narcotics or triptans; sleep, caffeine, etc.)No

    Form asks if headaches are caused by medication overuse/rebound or lifestyle factors

    Prior preventive therapy failure: Provider documents therapeutic failure or intolerance to applicable prior preventive medications (select all that apply: anti-epileptic drugs, beta-blockers, calcium-channel blockers, SNRIs, tricyclic antidepressants, Botox, alpha-agonists, ACE inhibitors/ARBs, or other)

    Select all that apply on form

    Concurrent CGRP use: Provider indicates whether Aimovig will be used concurrently with another CGRP inhibitor for acute use and, if yes, documents that benefits outweigh risks for concurrent use

    Form requires benefit/risk assessment if concurrent use is planned

    Reauthorization Criteria

    Reauthorization covered when ANY of the following documented improvement criteria are met (form specifies thresholds):

    Reauthorization response - chronic: Member experienced at least a 50% reduction in the number of migraine days per month compared to the start of therapy≥50% reduction

    Yes/No field on reauthorization section of form

    Reauthorization response - episodic: For episodic migraine, member experienced a reduction of at least 4 monthly migraine days since the start of therapy≥4 day reduction

    Yes/No field on reauthorization section of form

    The form requires explicit documentation that the member's headaches are not primarily due to medication rebound/overutilization or modifiable lifestyle factors. The form asks whether headaches are caused by medication overuse (defined on the form as taking narcotics or triptans exceeding more than 18 doses per month) or lifestyle contributors (for example, sleep patterns, caffeine use). A positive indication that headaches are caused by overuse or lifestyle factors implies the member may not meet coverage criteria unless those issues are addressed and documented.

    For reauthorization requests, the form specifies that ongoing coverage depends on documented clinical response. If the member does not meet the required improvement thresholds indicated on the form, continued therapy may be considered not medically necessary. The reauthorization questions require the provider to confirm whether the member has experienced either a ≥50% reduction in monthly migraine days overall or, for episodic migraine, a reduction of at least 4 monthly migraine days. A “No” response to these items supports discontinuation of coverage absent other documented justification.

    Response Thresholds and Coding Notes

    Reauthorization response thresholds
    Reauthorization response — chronicMember experienced at least a 50% reduction in migraine days per month compared to start of therapy
    Reauthorization response — episodicFor episodic migraine, member experienced a reduction of at least 4 monthly migraine days since start of therapy
    Form response captureYes/No checkboxes on reauthorization section to document outcomes

    Submission, Documentation, and Prior Authorization Steps

    Prior Authorization

    Submission and reauthorization requirements

    Submit a separate prior authorization form for each medication; complete all required fields on the form and fax the completed form and all clinical documentation to 1-866-240-8123 (mail option provided on form).

    • Submit a separate form for each medication.
    • Fax the completed form and all clinical documentation to 1-866-240-8123 (or mail per form instructions).
    • Print or type legibly in blue or black ink; prescribing physician should usually complete the form.
    • Provide physician address (required for physician notification).
    Step Therapy

    Prior therapeutic failures required

    Document therapeutic failure or intolerance to one or more prior migraine preventive medication classes by selecting all applicable agents on the form.

    Purpose and Scope

    This prior authorization form is used to request coverage for migraine prophylaxis with agents such as Aimovig. It collects the member's diagnosis categorized as Episodic Migraine Prophylaxis (4–14 headache days per month) or Chronic Migraine Prophylaxis (15 or more headache days per month), baseline average migraine days per month prior to therapy, history of medication overuse or lifestyle contributors, and prior preventive therapy failures. The information is used to determine initial eligibility and to establish baseline frequency for later reauthorization assessments.

    Key Definitions

    Episodic Migraine Prophylaxis
    Definition (episodic)4–14 headache days per month
    PurposeDetermines initial eligibility and baseline for reauthorization response assessment
    Chronic Migraine Prophylaxis
    Definition (chronic)15 or more headache days per month (of which a specified number are migraine days)
    PurposeDetermines initial eligibility and baseline for reauthorization response assessment
    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyMedication prior authorization form for Aimovig (migraine prophylaxis)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a separate completed prior authorization form and all clinical documentation by fax to 1-866-240-8123 for each medication.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaResponse Thresholds and Coding NotesSubmission, Documentation, and Prior Authorization StepsPurpose and ScopeKey Definitions
  1. Indicate failure/intolerance to anti-epileptic drugs (e.g., topiramate, valproic acid, divalproex sodium, carbamazepine).
  2. Indicate failure/intolerance to beta-blockers (e.g., propranolol, timolol, metoprolol).
  3. Indicate failure/intolerance to calcium-channel blockers (e.g., verapamil, amlodipine).
  4. Indicate failure/intolerance to SNRIs (e.g., venlafaxine, duloxetine) and tricyclic antidepressants (e.g., amitriptyline, nortriptyline).
  5. Indicate failure/intolerance to Botox, alpha-agonists (e.g., clonidine, guanfacine), or ACE/ARB (e.g., lisinopril, candesartan), as applicable.
  6. Select Other and list additional prior preventive therapies if needed.
  7. Documentation Required

    Required documentation to support prior authorization

    Complete all required member, provider, medication, and clinical information fields on the form to support the prior authorization request.

    • Member information: Subscriber ID, group number, member name, phone, DOB, address, state, ZIP (Chunk 1).
    • Provider information: Physician name, NPI, phone, fax, address, city, state, ZIP, suite/building, physician signature and date (Chunk 2).
    • Medication information: Drug name, strength, requested quantity, days supply (30/90/other), directions (Chunk 3).
    • Clinical information: diagnosis (episodic or chronic migraine), baseline migraine days/month, medication overuse/rebound status, prior therapy failures, concurrent CGRP use, and for reauthorization the response (≥50% reduction or ≥4 day reduction for episodic) (Chunk 4).
    • Fax the completed form and all clinical documentation to 1-866-240-8123 (Chunk 6).
    Denial Risk

    Incomplete forms or missing documentation may result in denial

    Incomplete forms or missing supporting clinical documentation may result in denial; the completed form plus all clinical records must be faxed to 1-866-240-8123.

    • Ensure all sections are completed and legible (print/type in blue or black ink).
    • Provide physician address and signature as required.
    • Include documentation of prior preventive therapy failures and baseline migraine frequency to avoid denial.